tbuckley/cabot-search huggingface dataset:
110P 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Authors: E. Rupp, R. Hajri, A. Rathakrishnan, G. Jardali, L. Lawrence, F. Griscelli, F. Blanc-Durand, A. Leary, P. Pautier, P. Saulnier, C. Jovelet, P.E. Bonte, N. Lassau, L. Lacroix, J. Michels
Journal: Annals of Oncology (2024)
132P The potential of VEGF-A in the peripheral blood serum as a biomarker of response in the addition of bevacizumab with chemotherapy-combined immunotherapy for metastatic nonsquamous non-small cell lung cancer
Authors: J. Sugisaka, K. Tanaka, Y. Shiraishi, Y. Watanabe, H. Daga, K. Azuma, K. Nishino, M. Mori, M. Terashima, H. Saito, A. Hata, T. Sakaguchi, T. Kozuki, N. Yamamoto, K. Nakagawa, I. Okamoto
Journal: Annals of Oncology (2024)
137P Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker
Authors: S. Salas, L. Nguyen-Phuong, F. Ginot, L. Greillier, P. Tomasini, A. Boutonnet, J.L. Deville, F. Fina, S. Benzekry
Journal: Annals of Oncology (2024)
249P Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Authors: L. Michel, M. Untch, A. Schneeweiss, C. Solbach, J-U. Blohmer, P.A. Fasching, P. Wimberger, C. Hanusch, M. Rezai, C. Denkert, H-J. Lueck, J. Huober, S. Schmatloch, K.E. Rhiem, M. Just, T. Link, E. Ladda, J. Rey, J. Holtschmidt, S. Loibl
Journal: Annals of Oncology (2024)
342MO Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real-world data analysis of genomics and targeted therapy sequencing
Authors: G. Parkinson, M. Lustberg, S. Nazari, A. Elliott, G. Sledge, R. Jeselsohn, E. Hsu, R.W. Sobol, A. Sandoval-Leon, R. Gopalakrishnan, I. Makhoul, L.E. Nye, A. Kurian, F. Lynce, S. Graff
Journal: Annals of Oncology (2024)
469P Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
Authors: M. Porte, K. Beshiri, K. Ouali, S. Postel-Vinay, C.P. Massard, Y. Loriot, S. Champiat, A. Hollebecque, C. Smolenschi, M. Sakkal, A. Gazzah, R. Bahleda, J-M. Michot, T. Hueso, A. Jeanson, E. Rouleau, L. Lacroix, C. Baldini
Journal: Annals of Oncology (2024)
92P Transformative diagnostics in urothelial carcinoma: Utilizing targeted NGS and LP-WGS for non-invasive detection and personalized medicine
Authors: H. Zhao, H. Tang, C. Jia, F. Xie, Y. Zhang, Z. Zhang, N. Wei, J. Xu, T. Xiao, H. Guo, S. Jia
Journal: Annals of Oncology (2024)
106P Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Authors: L. Bonanno, L.C. Bao, A. Padovan, A. Ferro, A. Bianco, L. Calvetti, A. Pavan, S. Ziampiri, E. Zulato, G.M. Marinato, A. Dal Maso, S. Frega, G. Pasello, V. Guarneri, S. Indraccolo
Journal: Annals of Oncology (2024)
349MO Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer
Authors: F. Ma, F. Qiu, Z. Tong, J. Wang, Y. Shi, Y. Zhang, G. Yu, H. Shi, X. Wu, A. Liu, Y. Zhang, H. Wang, Y. Cheng, H. Yang, H. Li, J. Chang, X. Xing
Journal: Annals of Oncology (2024)
81P FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs – Preliminary data after two years of enrollment
Authors: K. Jalkanen, E. Alanne, S.M.E. Iivanainen, O-S. Kääriäinen, M.M.E. Tanner, A. Färkkilä, M.V.J. Mustonen, J. Mattson
Journal: Annals of Oncology (2024)
231O Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III UNICANCER trial
Authors: S. Rivera, R. Ghodssighassemabadi, T. Brion, Y. Kirova, S. Racadot, M. Benchalal, J.B. Clavier, C. Brunaud, M-E. Fouche-Chand, D. Argo Leignel, K. Peignaux-Casasnovas, A. Benyoucef, D. Pasquier, P. Guilbert, J. Blanchecotte, G. Phothirath, A. Lamrani-Ghaouti, M. Bergeaud, G. Auzac, S. Michiels
Journal: Annals of Oncology (2024)
339TiP A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Authors: T. Foukakis, B. Naume, A. Karakatsanis, A. Andersson, E. Barnekow, L. Edman Kessler, Z. Einbeigi, O. Engebraten, F. Killander, B.K. Linderholm, A. Schiza, A. Valachis, J. Bergh, G. Villacampa, A. Zouzos, M. Hellström, J. Hartman, A. Matikas
Journal: Annals of Oncology (2024)
126P Genomic landscape and prognostic impact of HER2 low-expressing tumors
Authors: A. Shreenivas, A. Elliott, T. Corbiere, H-Z. Chen, B. George, M. Kamgar, S. Chakrabarti, A. Desai, Y. Boumber, C. Floudas, D. Bracken-Clarke, E. Xue, J. Thomas, J. Xiu, E.S. Antonarakis, R. Kurzrock
Journal: Annals of Oncology (2024)
440O First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase
Authors: G. Tabatabai, P. Freres, M. Glas, P. Hau, L. von Baumgarten, M.J. van den Bent, M.C. Burger, C. Seidel, U. Herrlinger, I. Mildenberger, B. Neyns, H. Schafer, A. Wick, M.H. Falk, L.L. de Freitas Chama, P.G. Kelemen, F. Schwenke, S.D. Koch, P. Romer Roche, U.S. Gnad-Vogt
Journal: Annals of Oncology (2024)
CN91 Toxicities in breast cancer patients undergoing neoadjuvant immune checkpoint inhibitor therapy: Insights from a nurse practitioner perspective
Authors: A.B. Rodriguez Garcia, Y. Torralba, B. Walbaum, E. Segui Solis, O. Martinez Saez, N. Bartolome, M. Alatamirano, E. Carcelero, G. Riu, F. Schettini, I. García-Fructuoso, R. Gómez Bravo, P.R. Rivera, T. Pascual, B. Adamo, M.J. Vidal Losada, M. Munoz, A. Prat, A. Domenech
Journal: Annals of Oncology (2024)
511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
Authors: C. Santos Vivas, J. Vidal Barrull, C. Fernandez Rodriguez, F. Salvà Ballabrera, V. Alonso-Orduna, R. Garcia-Carbonero, F. Losa, N. Tarazona Llavero, M.J. Safont Aguileria, F. Rivera Herrero, L. Layos Romero, M.J. Ortiz Morales, A. Salud, J. Alcaide-Garcia, D. Paez, X. Hernandez-Yagüe, R. Alvarez Gallego, R. Vera, B. Bellosillo Paricio, C. Montagut Viladot
Journal: Annals of Oncology (2024)
253P Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy
Authors: M. Carausu, D. Gacquer, X. Wang, S. Majjaj, D. Vincent, L. Buisseret, M. Ignatiadis, D. T'Kint de Roodenbeke, I. Veys, F. De Neubourg, J. Blanc, D. Larsimont, F. Rothé, C. Sotiriou
Journal: Annals of Oncology (2024)
314P The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients
Authors: M. Magbanua, S. Rivero-Hinojosa, R. Sayaman, T. Tin, E. Kalashnikova, D. Wolf, L. Brown-Swigart, G. Hirst, C. Yau, C. Isaacs, R.A. Shatsky, A. Delson, C.C. Palsuledesai, A.A. Rodriguez, M.C. Liu, P.R. Pohlmann, L. Esserman, H.S. Rugo, A. DeMichele, L.J. Van't Veer
Journal: Annals of Oncology (2024)
88P Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry
Authors: C. Le Tourneau, R. Dienstmann, A. Hackshaw, J. Geissler, A. Ferro, E. Cheese, E. Schirghuber, J-Y. Blay
Journal: Annals of Oncology (2024)
100P Predicting tumor ER and HER2 status using a cell-free RNA liquid biopsy assay
Authors: L.S. Schwartzberg, J. Yen, E. Boyle, T. Cavazos, M. Karimzadeh, H. Heydari, L. Fish, R. Trivedi, F. Hormozdiari, A. Lazar, B. Alipanahi
Journal: Annals of Oncology (2024)
517P Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study
Authors: A. Zaanan, E.S. Bergen, L. Evesque, A. Meurisse, P. Artru, T. Lecomte, O. Bouche, R. Coriat, A. Lievre, R. Cohen, V. Boige, S. Louafi, J-B. Bachet, J. Taieb, D. Vernerey, H. Blons, P. Laurent-Puig
Journal: Annals of Oncology (2024)
452MO Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial
Authors: E. Pineda, J.M. Sepúlveda, M. Valiente, M.Á. Vaz-Salgado, M. Martínez-García, M. Ruiz Vico, G. Velilla, M.A. Mazariegos-Rubi, I. Valduvieco, M. Castro-Henriques, L. Cano, S.G. Marcus
Journal: Annals of Oncology (2024)
524P A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies
Authors: A. Lim, S.Y. Kang, M.K. Choi, M.A. Lee, J.Y. Kim, D-H. Koo, S-H. Beom, S. Hong, J. Jo, Y.H. Kim, S. Lee
Journal: Annals of Oncology (2024)
159P Exploring programmed death cell-1 (PD-1) single nucleotide polymorphisms (SNP) as predictive biomarkers for immune-related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Authors: L. Liguori, G. Polcaro, V. Manzo, V. Pagliara, E. DeBellis, R. Martinelli, A. Filippelli, V. Conti, S. Pepe, F. Sabbatino
Journal: Annals of Oncology (2024)
165P Consistency analysis of c-Met protein expression over time in patients with non-squamous non-small cell lung cancer
Authors: A.B. Cortot, R. Dubois, V. Gregoire, J-B. Gibier, J. Labreuche, V. Deprez, D. Dubrulle, T. Chretien, E. Wasielewski, H. Behal, D. Feng, A. Lind, P.J. Ansell, R. Thiébaut, C. Hader
Journal: Annals of Oncology (2024)
533P First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Authors: D. Basile, F. Bergamo, E. Ongaro, M. Cinausero, V. Conca, M. Ambrosini, J. Lucchetti, G. rosati, A. Avallone, G. Di Paolo, E. Lai, E.S. Lutrino, P. Di Nardo, I.V. Zurlo, C. Cortese, M. carullo, S. Leo, S. Di Donato, F. Pietrantonio, G. Aprile
Journal: Annals of Oncology (2024)
142P Exploring tumor mutational burden and frameshift mutations as predictors of immune checkpoint inhibitor efficacy
Authors: M. Hoshino, T. Shimoi, T. Yamanaka, R. Kitadai, M. Ito, A. Saito, S. Kita, A. Kawachi, H.S. Okuma, A. Maejima, Y. Kojima, K. Sudo, E. Noguchi, T. Koyama, Y. Fujiwara, K. Yonemori
Journal: Annals of Oncology (2024)
CN9 Using the ‘person-based approach’ to adapt and optimise an eLearning resource to equip professionals to support families when a significant adult with children (&gt;18 years) is at end of life with cancer
Authors: S. Sheehan, C.J. Semple, J.R. Hanna, T. McCance, A. Drury, C. O'Neill
Journal: Annals of Oncology (2024)
128P Whole blood transcriptomics identifies transcriptional patterns linked to outcomes in patients receiving immune checkpoint inhibitors
Authors: S. Hone Lopez, S. Loipfinger, A. Bhattacharya, M. Jalving, S. Oosting, J.T.J.N. Hiltermann, M. de Bruyn, E.G.E. de Vries, J.J. De Haan, R.S.N. Fehrmann
Journal: Annals of Oncology (2024)
CN17 A multimedia method for pre-test genetic counselling in breast cancer patients: A pilot feasibility study
Authors: C.W.H. Chan, S.Y. Chair, S.W.W. Chan, J.Y.W. Chan, S.M. Chan, K.C. Choi, K.M. Chow, I.S. Soong, M.M.Y. Waye, W. Yeo
Journal: Annals of Oncology (2024)
556P Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Authors: W. Xiao, R. Sun, J. Guo, C. Li, R. Zhang, W. Fan, X. zhou, J. Teng, J. Zheng, L. Li, X. Wu, S. Chen, G. Chen
Journal: Annals of Oncology (2024)
CN87 Risk stratification for cardiotoxicity and follow-up in breast cancer patients treated with anthracycline and/or trastuzumab: An exploratory analysis of patient records
Authors: L-M. Kinnaer, J. Van Hulle, E. Naert, F. Tromp, A. De Pauw, H. Denys, N. Van Titelboom, D.F. Serruys
Journal: Annals of Oncology (2024)
550P The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Authors: R.A. Lunenberg, I.A. Franken, M.N.G.J.A. Braat, M. Elferink, F.H. van der Baan, M. Koopman, G. Vink, M. Intven, F. Sijtsma, J.M.L. Roodhart
Journal: Annals of Oncology (2024)
444O The prognostic impact of CDKN2A/B heterozygous deletions in IDH-mutant glioma
Authors: F.M. Ippen, T. Hielscher, K. Göbel, D. Friedel, D. Reuss, A. von Deimling, W. Wick, F. Sahm, A. Suwala
Journal: Annals of Oncology (2024)
134P Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)
Authors: A. Kulasinghe, R. Yan, S. Quinn, B. Falkenstein, J. Monkman, K.J. O'Byrne, S.C. Chennubhotla, F. Pullara
Journal: Annals of Oncology (2024)
123P Pan-cancer homologous recombination deficiency (HRD) evaluation in patients enrolled in a routine molecular screening program
Authors: P. Romero-Lozano, A. Hernando Calvo, E. Castillo, D.G. Lo Giacco, M. Vila-Casadesús, M. Gómez, G. Buono, V. Bach, M. Pereira, A. Onieva, A. Martin, J. Matito, P.G. Nuciforo, E. Garralda, E. Felip, C. Saura Manich, J.C. Galceran, C. Garcia Duran, J. Tabernero, A. Vivancos
Journal: Annals of Oncology (2024)
144P Analysis of a novel predictive marker of immune checkpoint response in head and neck cancer, calculated from histopathological slides through inferred transcriptomics
Authors: J. Arnon, O. Tirosh, L. Gugel, G. Dinstag, Y. Kinar, A. Elia, M. Tabi, T. Gottlieb, E. Pikarsky, R. Aharonov, A. Popovtzer
Journal: Annals of Oncology (2024)
449MO Macrophage derived immunotherapy in glioblastoma: Phase I TEM-GBM-001 results
Authors: F. Ciceri, F. Farina, B. Gentner, M. Eoli, M. Barcella, E. Anghileri, Q.G. D'alessandris, V. Ferla, A. Franzin, F. Gagliardi, F. Legnani, A. Capotondo, S. Mazzoleni, A. Olivi, R. Pallini, M. Saini, S. Snider, L. Naldini, C. Russo, G. Finocchiaro
Journal: Annals of Oncology (2024)
87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making
Authors: F.U. Usman, S.Y. Sabag, E. Bhang, M. Kamali, S. Pollard, A. Hussein, J. Ko-Leong, C. Hughesman, D. Alex, P. Demarco, D. Weymann, J.M. Loree, K. Gill, Y. Wang, J. Laskin, D. Regier, H. Lim, S. Chia, S. Yip, C. Ho
Journal: Annals of Oncology (2024)
CN3 Existential distress in head-and-neck male cancer patients: A comprehensive study of demographic factors
Authors: L. Sanz Monge, J. Garrido Gallego, P. Palao Contell, P.J. Gomez Garcia, C. Pertusa Gomez, L. Santa Cruz Ramis, A.J. Cunquero Tomas, A. Berrocal
Journal: Annals of Oncology (2024)
111P Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Authors: V. Debien, S. Taleb, S. Cousin, L. Belcaid, A. Bayle, I. Taleb, A. Besson, N. El Ghazzi, A. Moreau, Y. Laizet, M. Alamé, D. Vasseur, L. Blouin, E. Khalifa, L. Lacroix, I. Soubeyran, E. Rouleau, C.P. Massard, A. Italiano
Journal: Annals of Oncology (2024)
431P Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)
Authors: H.S. Rugo, A. Bardia, S-A. Im, S. Pernas Simon, M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges, D. Cescon, M. Hattori, Y-S. Lu, J. Tsurutani, S.M. Tolaney, D. Mapiye, K. Atuah, D. Verma, S. Khan, B. Xu, B. Pistilli, K. Jhaveri
Journal: Annals of Oncology (2024)
473P A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)
Authors: M. Polano, E. Cella, M. Padovan, A. Bosio, M. Caccese, G. Cerretti, G. Toffoli, G. Lombardi
Journal: Annals of Oncology (2024)
438TiP Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress)
Authors: Y. Fan, H. Li, H. Li, Z. Song, L. Xu, J. Yang, J. Yao, D. Ji, Y. Han, H. Yu, B. Xu
Journal: Annals of Oncology (2024)
371P Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial
Authors: S. Wang, R. Hong, F. Xu, W. Xia, Y. Teng, Q. Ouyang, None Z. yuan, K. Jiang, Y. Lin, X. Liu, Q. Chen, None X. Wu, None Y. Shi, None J. Huang, X. An, C. Xue, X. Bi, Q. Zheng, M. Chen, H. Li
Journal: Annals of Oncology (2024)
CN101 Continuous care unit for patients with cancer: Identification of the user profile and follow-up needs
Authors: I. Casablancas, A. Rosich-Soteras, L. Villa, C. Cristina, S. Falcon, B. Merchan, F. Fernández Avilés, L. Corominas, A. Domenech
Journal: Annals of Oncology (2024)
108P Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Authors: C. Smolenschi, R. Sharaf, A. Hollebecque, M.A. Bani, V. Boige, A. Boileve, M. Valery, A. Italiano, A. Tarabay, F. Facchinetti, T. Pudlarz, R. Bahleda, A.C. Fuerea, L. Benhaim, I. Sourouille, A. Bayle, M. Gelli, E. Fernandez de Sevilla, M.P. Ducreux, D. Vasseur
Journal: Annals of Oncology (2024)
411P Interim analysis of prospective observational study to evaluate the impact of cancer gene panel tests on treatment decision making in metastatic or recurrent breast cancer in Japan: JBCRG-C07 REIWA study
Authors: H. Masuda, M. Hattori, H. Tada, Y. Sagara, Y. Adachi, T. Iwatani, Y. Uemoto, Y. Otani, Y. Kajiwara, D. Kitagawa, T. Kogawa, T. Shien, Y. Tanabe, M. Tanioka, F. Hara, H. Yasojima, K. Yoshimura, H. Iwata, N. Masuda
Journal: Annals of Oncology (2024)
127P Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors
Authors: D.A. Gomez Puerto, A. Rossi, A. Hernando Calvo, J.M. Ucha Hermida, M. Gómez, J. Matito, M. Vila-Casadesús, D. Morchón Araujo, R. Dienstmann, J.C. Galceran, D.G. Illescas, T. Macarulla Mercade, E. Garralda, C. Saura Manich, M.E. Elez Fernandez, E. Felip, J. Tabernero, A. Vivancos
Journal: Annals of Oncology (2024)
456P Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
Authors: M.A. Mazariegos-Rubi, R. Gironés Sarrió, S. del Barco, A. Garcia Castano, G. Velilla, M. Domenech Vinolas, M. Alonso Garcia, L. Ferreira Freire, N. Luque Caro, I. Fernandez Perez, T. Quintanar Verduguez, S. Peralta Muñoz, I. Ceballos Lenza, E. Iza Rodriguez, C. Sanfeliz, E. Pablo Martín, E. Almagro Casado, J.M. Mazarico, A. Esteve, E. Pineda
Journal: Annals of Oncology (2024)
537P Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Authors: Y. Chen, K. Wang, Z. Zhang, H. Zhang, W. Yang, R. Wu, M. Zhou, Z. Zhang, F. Xia
Journal: Annals of Oncology (2024)
352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)
Authors: N. Wortelboer, S. Kent, I.R. Konings, A. Van Ommen-Nijhof, V. van der Noort, E. van den Pol, C. Guerrero Páez, M. van Bekkum, H.J. Droogendijk, F. Erdkamp, D. Houtsma, H.M. Oosterkamp, A. van der Padt-Pruijsten, E.J. Siemerink, J. Tol, A.A. van Zweeden, A.E. van Leeuwen-Stok, G.S. Sonke, A. Jager, H.M. Blommestein
Journal: Annals of Oncology (2024)
362P Dose reductions due to treatment-related side effects and survival outcomes in breast cancer patients treated with CDK4/6 Inhibitors
Authors: P. Kubilay Tolunay, B. Kurt Inci, S. Usta, A. Topkac, B. Karabuga, E. Aydemir, C. Karacin, O. Ates
Journal: Annals of Oncology (2024)
374P Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany
Authors: M. Campone, J-S. Frenel, V.I.I. Kiver, A. Woeckel, A.G. Kerscher, M. Krebs, C.S. Leal, V.M. Saglimbene, N. Trankov, N. Sadetsky, N. Sjekloca, O. Libert, A.G. Kaushik, F. Bocquet
Journal: Annals of Oncology (2024)
363P Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer
Authors: S.M. Buijs, M.I. Mohmaed Ali, E. Oomen-de Hoop, C.L. Braal, N. Wortelboer, A. Van Ommen-Nijhof, G.S. Sonke, I.R. Konings, A. Jager, N. Steeghs, H. Siebinga, R.H. Mathijssen, A.D.R. Huitema, S.L. Koolen
Journal: Annals of Oncology (2024)
443O A perioperative study of safusidenib in patients with IDH1 mutated glioma
Authors: J.R. Whittle, M. Rosenthal, M. Spiteri, S. Cain, M.D. Topp, S. Shaya, J. Jones, A. Valkovic, O. Fatunla, J. Dimou, R. Tobler, S. Roberts-Thomson, D. McArdle, E. Lui, B. Nijagal, S.M. Grimmond, S.A. Best, S. Freytag, K. Drummond
Journal: Annals of Oncology (2024)
CN94 Associations between depression and quality of life after hematopoietic stem cell transplantation: A longitudinal study
Authors: A. Rosich-Soteras, C. Gallego, L. Guardia-Roca, E. Güell, C. Ramos-Serrano, A. Serrahima-Mackay, T. Solano-Moliner, N. Jaramillo-Forcada, A. Domenech, A. Zabalegui
Journal: Annals of Oncology (2024)
395P Receptor status heterogeneity during metastatic breast cancer treatment
Authors: S. Geurts, K. Hermans, F. Van den Berkmortel, J. Tol, J.B. Heijns, M. Dercksen, B.E.P.J. Vriens, K. Aaldering, M. Pepels, N. Peters, L. van de Winkel, E. Boon, N. Teeuwen, M. van Kats, V. Tjan-Heijnen
Journal: Annals of Oncology (2024)
534P Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Authors: A. Cordua, D. Basile, S. Sperotto, L. Foltran, M. Casagrande, M. carullo, F. Morano, J. Lucchetti, G. Rosati, A. Avallone, E. Lai, E.S. Lutrino, A. Parnofiello, M. Guardascione, A.G. Leone, I.V. Zurlo, V. Conca, S. Leo, S. Lonardi, G. Aprile
Journal: Annals of Oncology (2024)
365P Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Authors: M. Oliveira, M. Gion Cortes, K.H. Jung, None B. bermejo, S.A. Hurvitz, S. Sadeghi, S. Wander, S-A. Im, E. Gal-Yam, J. Zhu, R. Schwab, H. Ngo, A. Collier, M. Cannon, C. Cahuzac, P.D. Perez Moreno, S. Mcintosh, C. Saavedra Serrano, A. Sonnenblick
Journal: Annals of Oncology (2024)
516MO Zanidatamab (Zani) + chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic colorectal cancer (mCRC)
Authors: S.Y. Rha, K-W. Lee, S. Lee, Y-K. Kang, S. Chandana, A. Escalante, C. Xie, P. Garfin, S. Iqbal
Journal: Annals of Oncology (2024)
439TiP AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors
Authors: A. Dowlati, D.L. Richardson, P. Lorusso, A.I. Spira, B. Bashir, M. Hirmand, M. Mehta, M.R. Patel
Journal: Annals of Oncology (2024)
344MO ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
Authors: F. Ma, F. Qiu, Z. Tong, J. Wang, Y. Shi, L. Li, G. Yu, H. Shi, X. Wu, A. Liu, Y. Zhang, H. Wang, Y. Cheng, H. Yang, H. Li, J. Chang, Q. Zhou
Journal: Annals of Oncology (2024)
385P A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Authors: D.B. Page, L. Kaur, E.C.C. Hong, A. Su, N. Moxon, S. Mellinger, T. Kelly, A. Kelley, N. Fredrich, A. Seino, G. Liberatore, A.K. Conlin, Z. Topp, K. Perlewitz, S. Stanton, Y. Wu, T.A. Traina, A. Gucalp
Journal: Annals of Oncology (2024)
429P Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives
Authors: A.L.V. Matos, M.S. van Ramshorst, V. Mueller, E. Agostinetto, S. Linn, M. Lambertini, V.C. Dieras, F. Le Du, S. Braga, C. Criscitiello, K. Jerzak, G. Morgan, S. Brucker, P. von Kroge, R. Haidinger, E. Schumacher-Wulf, M. Fontes e Sousa, F. Schettini, E. Laakmann
Journal: Annals of Oncology (2024)